Reneo Pharmaceuticals

OverviewSuggest Edit

Reneo Pharmaceuticals is a pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, to treat rare diseases such as fatty acid oxidation disorders and primary mitochondrial myopathies.

TypePublic
Founded2018
HQSan Diego, CA, US
Websitereneopharma.com

Latest Updates

Employees (est.) (Jun 2021)17(+42%)
Share Price (Oct 2021)$7(-9%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Reneo Pharmaceuticals

Gregory J. Flesher

Gregory J. Flesher

President, Chief Executive Officer
Mike Grey

Mike Grey

Executive Chairman
Alejandro Dorenbaum

Alejandro Dorenbaum

Chief Medical Officer
Vinny Jindal

Vinny Jindal

Chief Financial Officer
Wendy Johnson

Wendy Johnson

Chief Development Officer
Lynn Purkins

Lynn Purkins

Vice President of Clinical Operations
Show more

Reneo Pharmaceuticals Office Locations

Reneo Pharmaceuticals has offices in San Diego, Irvine and Sandwich
San Diego, CA, US (HQ)
12230 El Camino Real #230
Irvine, CA, US
18575 Jamboree Rd 275 s
Sandwich, GB
Discovery Park, Ramsgate Rd
Show all (3)

Reneo Pharmaceuticals Financials and Metrics

Reneo Pharmaceuticals Revenue

USD

Net income (Q2, 2021)

(9.2m)

EBIT (Q2, 2021)

(9.2m)

Market capitalization (21-Oct-2021)

169.7m

Closing stock price (21-Oct-2021)

7.0

Cash (30-Jun-2021)

140.4m
Reneo Pharmaceuticals's current market capitalization is $169.7 m.
Annual
USDFY, 2019FY, 2020

General and administrative expense

2.4m3.6m

R&D expense

13.1m15.9m

Operating expense total

15.5m19.6m

EBIT

(15.5m)(19.6m)
Quarterly
USDQ1, 2021Q2, 2021

General and administrative expense

1.7m2.9m

R&D expense

5.5m6.3m

Operating expense total

7.2m9.2m

EBIT

(7.2m)(9.2m)
Annual
USDFY, 2019FY, 2020

Cash

17.5m53.6m

Prepaid Expenses

519.0k1.4m

Current Assets

25.4m55.0m

PP&E

79.0k69.0k
Quarterly
USDQ1, 2021Q2, 2021

Cash

91.2m140.4m

Prepaid Expenses

2.3m3.8m

Current Assets

93.6m171.1m

PP&E

81.0k85.0k
Annual
USDFY, 2019FY, 2020

Net Income

(12.4m)(19.5m)

Depreciation and Amortization

34.0k37.0k

Accounts Payable

1.0m1.5m

Cash From Operating Activities

12.5m18.5m
Quarterly
USDQ1, 2021Q2, 2021

Net Income

(7.2m)(16.4m)

Depreciation and Amortization

10.0k20.0k

Accounts Payable

(927.0k)(1.2m)

Cash From Operating Activities

(8.6m)(18.3m)
USDFY, 2019

Financial Leverage

-1.1 x
Show all financial metrics

Reneo Pharmaceuticals Operating Metrics

May, 2021

Facility Space (UK), sq. ft.

1.46 k

Facility Space (US), sq. ft.

3.75 k

Trademarks (US)

1
Show all operating metrics

Reneo Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Reneo Pharma Ltd

Reneo Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Reneo Pharmaceuticals Online and Social Media Presence

Embed Graph

Reneo Pharmaceuticals News and Updates

Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001

IRVINE, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it has received a notic…

Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer

IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Ashley F. H…

Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies

IRVINE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will host a …

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will be part…

Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results

First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies

Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study

IRVINE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the first patient has been…
Show more

Reneo Pharmaceuticals Frequently Asked Questions

  • When was Reneo Pharmaceuticals founded?

    Reneo Pharmaceuticals was founded in 2018.

  • Who are Reneo Pharmaceuticals key executives?

    Reneo Pharmaceuticals's key executives are Gregory J. Flesher, Mike Grey and Alejandro Dorenbaum.

  • How many employees does Reneo Pharmaceuticals have?

    Reneo Pharmaceuticals has 17 employees.

  • Who are Reneo Pharmaceuticals competitors?

    Competitors of Reneo Pharmaceuticals include IntraBio, Momotaro Gene and GeneQuine Biotherapeutics.

  • Where is Reneo Pharmaceuticals headquarters?

    Reneo Pharmaceuticals headquarters is located at 12230 El Camino Real #230, San Diego.

  • Where are Reneo Pharmaceuticals offices?

    Reneo Pharmaceuticals has offices in San Diego, Irvine and Sandwich.

  • How many offices does Reneo Pharmaceuticals have?

    Reneo Pharmaceuticals has 3 offices.